Biocon has named Claire Mazumdar, niece of founder Kiran Mazumdar-Shaw, as part of its future leadership succession plan
She leads Bicara Therapeutics, became CEO in 2018, and has driven the company’s growth
Under her, Bicara Therapeutics listed in 2024, crossed $1.6 billion valuation, with trial risks remaining
Claire Mazumdar is emerging as a potential successor at Biocon, led by founder Kiran Mazumdar-Shaw. The company has outlined a succession plan that names her niece as a future leader of the biotechnology group.
Claire brings experience across biotechnology, venture capital and corporate strategy, placing her in line for a bigger leadership role.
She currently leads Bicara Therapeutics, a US-based oncology firm backed by Biocon. She took over as CEO in 2018 and has guided the company through a key growth phase.
1 May 2026
Get the latest issue of Outlook Business
Under her leadership, Bicara went public in 2024 with a Nasdaq listing. Its valuation has since crossed $1.6 billion, even as its lead cancer therapy remains under trials. This shows her ability to grow biotech businesses, but also highlights the risks, as outcomes depend heavily on research success.
Biotech Growth
Claire’s experience covers biotechnology, venture capital and corporate strategy. She also serves on the boards of Relay Therapeutics and Noora Health, strengthening her industry presence.
Her possible move at Biocon comes as the company reshapes itself for global growth. It has merged key verticals, simplified operations and reduced debt.
The biosimilars business now contributes nearly 60% of revenue. The company has 12 products already in the market and around 20 more in the pipeline, giving it a strong base for future growth.
Claire Net Worth & Assets
As of April 2026, Claire Mazumdar’s net worth is estimated between $8.3 million and $10.1 million, as per media reports. A large share is linked to her holdings in Bicara Therapeutics.
She owns over 362,000 shares in the company, making equity her main asset. This estimate does not include other personal investments or assets.
Her income mainly comes from executive pay and stock-linked incentives. At 37, her wealth outlook remains closely tied to Bicara Therapeutics’ performance going forward.
